Search our science

Tiede A, Abdul Karim F, Jiménez-Yuste V, Klamroth R, Lejniece S, Suzuki T, Groth A, Santagostino E. Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model. Haematologica.

Carcao M, Kearney S, Lu MY, Taki M, Rubens D, Santagostino E, Shen C. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B. Thromb Haemost.

Wu R, Sun J, Xu W, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Matytsina I, Zhang S, Pluta M, Yang R. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. Ther Clin Risk Manag. 2020;16:567-578

Bjørnsdottir I, Støvring B, Søeborg T, Jacobsen H, Sternebring O. Plasma polyethylene glycol (PEG) levels reach steady state following repeated treatment with N8-GP (turoctocog alfa pegol; Esperoct®). Drugs R D. 2020.

Wang M, Peltier S, Baumann K, Sidonio R, Witkop M, Cooper D, Waters E, Kahan S, Croteau S, Cutter S, Hernandez G, Wicklund B, Dreyer Gillette M, Haugstad K, Ostrow V, Nadglowski J. ACTION-TO-HOPE HCP and Consumer Results Supplement. Haemophilia. 2020;26(S1):3-19.

Tiede A, Cid AR, Goldmann G, Jiménez-Yuste V, Pluta M, Lissitchkov T, May M, Matytsina I, Miljic P, Pabinger I, Persson P. Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients With Severe Haemophilia A. Thromb Haemost. 2020;120(2):277-288.

Escuriola-Ettingshausen C, Korsholm L, Matytsina I, Schutgens R. Safety and efficacy of turoctocog alfa in severe and moderately severe previously treated patients with haemophilia A: interim results after >4,000 exposure days (guardian 5). Hemofili Vakalarla Egitim Sempozyumu - 6. 2020.

Forsyth A, Blamey G, Lobet S, McLaughlin P. Practical guidance for non-specialist physical therapists managing people with hemophilia and musculoskeletal complications. Health. 2020;12(2):158-179.

Burnier L, Brunsgaard Hermit M, Hilden I, Ezban M, Reedtz Kjellev SL. Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate. American Society of Hematology - 61st Annual Meeting. 2019.

Walsh KS, Mraskotsky C, Shapiro KA, Wilkening GN, Croteau SE, Rajpurkar M, Buranahirun C, Hannemann C, Maruff P, Ventola P, Cooper DL. A Methodologic Approach to Assessment of Cognitive Function in Congenital Hemophilia Using Hemophilia Normative Data (eTHINK) to Assess Children Exposed to GlycoPEGylated Factor IX (N9-GP) in the paradigm 5/6 Trials. International Neuropsychological Society - 48th Annual Meeting. 2020;

Walsh KS, Mraskotsky C, Shapiro KA, Wilkening GN, Croteau SE, Rajpurkar M, Buranahirun C, Hannemann C, Maruff P, Ventola P, Cooper DL. A Methodologic Approach to Assessment of Cognitive Function in Congenital Hemophilia Using Hemophilia Normative Data (eTHINK) to Assess Children Exposed to GlycoPEGylated Factor IX (N9-GP) in the paradigm 5/6 Trials. International Neuropsychological Society - 48th Annual Meeting. 2020;

Olsen AA, Grage H, Kryger K, Melchiorsen CR. Turoctocog alfa pegol, the only extended half-life FVIII product stable up to 40°C. European Association for Haemophilia and Allied Disorders - 13th Annual Congress. 2020.

Rose TH, Hollensen C, Agersø H, Ingwersen SH, Overgaard RV. Phase 2 concizumab population pharmacokinetic and exposure-response analyses: Application to phase 3 dose selection. European Association for Haemophilia and Allied Disorders - 13th Annual Congress. 2020.

Kjellev S, Østergaard H, Greisen PJ, Hermit MB, Thorn K, Hansen BG, Zhou R, Zhiru Y, Bjelke JR, Kjalke M, Lund J, Holm TL, Ley CD, Madsen DE, Thygesen P, Loftager M, Gandhi P, Lamberth K, Rasch MG, Egebjerg T, Lund S, Lorenzen N, Henriksen A, Rahbek-Nielsen H, Hilden I. Preclinical characterisation of Mim8 – A next-generation FVIII mimetic bispecific antibody. Haemophilia. 2020;26(S2):43-44. P035.

Ley CDD, Kjalke M, Holm TL, Madsen DE, Holmberg HL, Lauritzen B, Larsen LF, Bjelke JR, Stavenuiter F, Loftager M, Hermit MB, Hilden I, Kjellev SR. Improved effect of Mim8, a next-generation FVIII mimetic, translates from human in vitro to humanized mouse and cynomolgus models. Haemophilia. 2020;26(S2):40. P028.

Kjellev S, Østergaard H, Greisen PJ, Hermit MB, Thorn K, Hansen BG, Zhou R, Zhiru Y, Bjelke JR, Kjalke M, Lund J, Holm TL, Ley CD, Madsen DE, Thygesen P, Loftager M, Gandhi P, Lamberth K, Rasch MG, Egebjerg T, Lund S, Lorenzen N, Henriksen A, Rahbek-Nielsen H, Hilden I. Preclinical characterisation of Mim8 – A next-generation FVIII mimetic bispecific antibody. European Association for Haemophilia and Allied Disorders - 13th Annual Congress. 2020.

Ley CDD, Kjalke M, Holm TL, Madsen DE, Holmberg HL, Lauritzen B, Larsen LF, Bjelke JR, Stavenuiter F, Loftager M, Hermit MB, Hilden I, Kjellev SR. Improved effect of Mim8, a next-generation FVIII mimetic, translates from human in vitro to humanized mouse and cynomolgus models. European Association for Haemophilia and Allied Disorders - 13th Annual Congress. 2020.

Rose TH, Hollensen C, Agersø H, Ingwersen SH, Overgaard RV. Phase 2 concizumab population pharmacokinetic and exposure-response analyses: Application to phase 3 dose selection. Haemophilia. 2020;26(S2):127-128. P196.

Olsen AA, Grage H, Kryger K, Melchiorsen CR. Turoctocog alfa pegol, the only FVIII stable for up to 40 degrees Celsius with extended half-life. Haemophilia. 2020;26(S2):28-29. P004.

Marlar R, Strandberg K, Shima M, Adcock D. Clinical utility and impact of the use of the chromogenic versus one-stage factor activity assays in haemophilia A and B. Eur J Haematol. 2020;104(1):3-14.

Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8 GP; ESPEROCT®) assay performance: Implications for post-administration monitoring. Haemophilia. 2019;26(1):156-163.

Hassan Yaish, Tadashi Matsushita, Meriem Fadila Belhani, Víctor Jiménez Yuste, Kaan Kavakli, Lars Korsholm, Irina Matytsina, Claire Philipp, Kirsten Reichwald, Runhui Wu. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: results from the guardian 4 multinational clinical trial. Haemophilia. 2020;26(1):64-72.

Kjalke M, Kjelgaard-Hansen M, Andersen S, Hilden I. Thrombin Generation Assay in Plasma from Hemophilia A Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC. Blood. 2019;134(Suppl 1):3639.

Chitlur M, Carcao M, Cooper D, Jain S, Kavakli K, Kerlin B, Peltier S, Poon M-C, Saad H, Shapiro A. An Update on rFVIIa Use in Females with Rare Bleeding Disorders. N/A.

Chitlur M, Carcao M, Cooper D, Jain S, Kavakli K, Kerlin B, Peltier S, Poon M-C, Saad H, Shapiro A. An Update on rFVIIa Use in Females with Rare Bleeding Disorders. N/A.

Ley CD, Holm TL, Holmberg HL, Madsen DE, Bjelke JR, Loftager M, Lauritzen B, Hermit MB, Hilden I, Kjellev SLR. Next-generation FVIII mimetic shows superior effect in a FIX- and FX-humanized mouse model in vivo. American Society of Hematology - 61st Annual Meeting. 2019.

Kjalke M, Kjelgaard-Hansen M, Andersen S, Hilden I. Thrombin Generation Assay in Plasma from Hemophilia A Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC. Blood. 2019;134(Suppl 1):3639.